Key result
Coxsackie B virus IgM and IgG antibody positivity rates did not significantly differ between patients with postviral fatigue syndrome and matched controls (IgM: 24.4% vs 22.6%).
Why the study?
Does coxsackie B virus antibody testing help diagnose postviral fatigue syndrome?
Population
243 patients referred with postviral fatigue syndrome and age and sex matched controls
Comparison
Coxsackie B virus antibody testing and… vs Age and sex matched controls
Design
Case-control, blind analysis of blood sample
Follow-up
six months
Authors
Loading...
Coxsackie B serology lacks diagnostic utility in postviral fatigue syndrome; leaves open viral etiology for prospective studies.
Case-Control (n=486)
Blinded analysis
No
Does coxsackie B virus antibody testing help diagnose postviral fatigue syndrome?
Absolute Event Rate: 24.4% vs 22.6%
Serological tests for coxsackie B virus antibodies do not help diagnose postviral fatigue syndrome, as positive rates reflect background population levels.
Miller et al. (1991) conducted a case-control in Postviral fatigue syndrome (n=486). Coxsackie B virus infection vs. Age- and sex-matched controls was evaluated on Coxsackie B virus IgM positivity at entry. Coxsackie B virus IgM and IgG antibody positivity rates did not significantly differ between patients with postviral fatigue syndrome and matched controls (IgM: 24.4% vs 22.6%).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: